

EACR

European Association
for Cancer Research

CONFERENCES

www.eacr.org

EACR Conference

Liquid Biopsies

22-24 September 2026 | Lyon, France

Scientific Programme Committee

Ellen Heitzer (Chair)

Claus Lindbjerg Andersen

An Hendrix

Nikolas Stoecklein

Scan the QR code to access online conference
resources, including poster abstracts

Tag us   @helloeacr | Wi-Fi network: invites

Login option 1: z539017 | password: VK3gPSMH

Login option 2: z539015 | password: Yej63y5m



EACR onsite team



Chris Iliffe
Conference Officer



Kathryn Wass
Conferences Manager



Steph Milsom
Marketing Officer


Conference dinner

Optional ticketed event, Wednesday 23 September, 19:30 (SOLD OUT)

The conference dinner will take place on the second night of the meeting. It will be an excellent opportunity for participants and speakers to get to know each other in a relaxed and informal environment. Smart dress required.

It is important that you bring your participant badge with you to La Maison for entry to the restaurant otherwise you may not be permitted entry. Please do not arrive at the venue any earlier than 19:20.

La Maison Restaurant, 4 Rue Jonas Salk, 69007 Lyon



EACR Conference CHROMOSOMES IN CRISIS:

From Chromosomal
Instability to Catastrophes
in Cancer Genomes

3 - 5 November 2026, Berlin

eacr.org/conferences



16 top speakers including:

Christina Curtis	John Maciejowski
Daniele Fachinetti	Sarah McClelland
Jan Korbel	Serena Nik-Zainal
Susanne Lens	Ofer Shoshani

**Uncover how chromosomal
chaos shapes cancer
biology and opens new
avenues for clinical
intervention**

- Genetics & genomics of chromosomal catastrophes
- Emerging technologies & model systems to measure and study chromosomal instability
- Therapeutic vulnerabilities & clinical opportunities
- Various chromosomal alterations, their formation and cellular consequences

14 top speakers including:

Chiara Ambrogio	Alfredo Gimenez Cassina
Alberto Bardelli	Marta Puyol
Rene Bernards	Giulia Siravegna
Alejo Efeyan	Alexia-Ileana Zaromytidou

Professional development for cancer researchers

Information, insight and
strategies to develop a
successful career in cancer
research.

- Career opportunities after a PhD
- Equality, inclusion and diversity
- Grant writing
- Ethical and productive use of AI

EACR European Association
for Cancer Research

CAREER MASTERCLASS

FOR EARLY CAREER
CANCER RESEARCHERS

Virtual event | 17 - 18 November 2026

eacr.org/conferences



EACR Conference

OVERCOMING THERAPY RESISTANCE:

Outsmarting intratumour
heterogeneity and
plasticity

20 - 22 April 2027, Lyon

eacr.org/conferences



14 top speakers including:

Nicola Aceto	Frederic de Sauvage
Marta Kovatcheva	Tuomas Tammela
Ilaria Malanchi	Celine Vallot
Chris Marine	Ashani Weeraratna

Tackling one of oncology's most persistent challenges

- Resolving tumour complexity
- Driver cancer cell states: MICs, persister cells, and dormancy
- Dissecting and rewiring the dynamic tumour microenvironment (TME)
- Emerging treatment strategies to contend with ITH and plasticity
- Where and when to treat: timing and sequencing of intervention

14 top speakers including:

Hana Aliee	Lichun Ma
Charlotte Bunne	Eytan Ruppin
Trey Ideker	Aristotelis Tsirigou
Mo Lotfollahi	Linghua Wang

where models help, where they fall short, and what comes next

- Single-cell and spatial omics in cancer
- Computational and digital pathology
- Multimodal integration across imaging, pathology, genomics, and clinical data
- Foundation models, representation learning, and generative modeling
- Modeling cellular perturbation and treatment response for precision oncology
- Cancer genomics, tumour evolution, heterogeneity, and the tumour microenvironment

EACR Conference

CANCER BIOLOGY:

Virtual Systems & Beyond

16 - 18 March 2027, Bergamo

eacr.org/conferences



EACR Conference: Liquid Biopsies

Tag us   @helloeacr | Wi-Fi: invites Login: z539017 Password: VK3gPSMH

Day 1 | Tuesday 22 September

From 11:30

REGISTRATION

Session 1
posters can be
put up

12:00-13:00

 WELCOME REFRESHMENTS

A chance to meet fellow attendees and enjoy a light buffet

13:00-13:10

CONFERENCE WELCOME

Scientific Programme Committee

SESSION 1: UNVEILING THE BIOLOGY BENEATH
THE BIOMARKERS: MECHANISMS DRIVING LIQUID
BIOPSY SIGNALS Chair: Ellen Heitzer

13:10-13:40

OPENING KEYNOTE LECTURE

Q&A: 13:40-13:55

Efrat Shema Weizmann Institute of Science, Israel

'Single-molecule epigenetic analysis of plasma-circulating nucleosomes for cancer diagnosis'

13:55-14:15

Amin El-Heliebi Medical University Graz, Austria

Q&A: 14:15-14:25

'Integrating liquid biopsy and spatial transcriptomics for understanding ctDNA release'

14:25-14:35

Sangmi Lee Harvard Medical School, USA

Q&A: 14:35-14:40

Proffered Paper 1: 'Mechanistic interpretation of cfDNA fragmentation topography through joint deconvolution of fragmentation processes and tissue composition with cfVista'

14:40-15:00

EXHIBITOR INTRODUCTIONS

60-second intro pitches by each company

15:00-15:30

 COFFEE BREAK, EXHIBITION & SOLO MEET-UP

Solo travellers are invited to meet up at the EACR banner in the exhibition hall to connect with fellow adventurers

15:30-15:50

Remond Fijneman NKI, Netherlands

Q&A: 15:50-16:00

'Impact of tumor location and host factors on ctDNA shedding'

16:00-16:10

Mischa Steketee Amsterdam UMC, Netherlands

Q&A: 16:10-16:15

Proffered Paper 2: 'Tumor-Informed Deconvolution of Circulating Extracellular Vesicle RNA in Large B Cell Lymphoma Patients Reveals On-treatment Tumor-Microenvironment Evolution'

16:15-16:25 Q&A: 16:25-16:30	Marie Bernkopf St. Anna Children's Cancer Research Institute, Austria Proffered Paper 3: 'Sensitive detection of relapse and immunotherapy targets by blood and bone marrow multi-modal liquid biopsy analysis in high-risk neuroblastoma'
16:30-16:40	POSTER SPOTLIGHTS <i>Posters 1, 30 and 55 will be presented in short 3-minute 'flash talks'</i>
16:40-17:00 Q&A: 17:00-17:10	BIOMODAL SYMPOSIUM Tom Charlesworth biomodal 'Single stranded 6-base workflow optimises discovery of integrated genetic, epigenetic and fragmentomic biomarkers for sensitive ctDNA detection'
17:10-17:50	PANEL DISCUSSION 'Where is liquid biopsy heading in the next 5-10 years? Clinical implementation, standardisation and regulatory challenges'
17:50-18:20	 WELCOME RECEPTION <i>with drinks and a light buffet</i>
18:20-19:50	POSTER DISCUSSION SESSION 1 <i>Presenters of posters 1-61 should stand by their boards.</i>

Day 2 | Wednesday 23 September

08:15-08:45	EARLY POSTER VIEWING
08:45-09:00	SESSION 2: TRACKING THE UNSEEN - LIQUID BIOPSIES IN ADVANCED AND METASTATIC CANCER Chair: Claus Lindbjerg Andersen
09:00-09:20 Q&A: 09:20-09:30	ULTIMA GENOMICS SPOTLIGHT Alex Watkins Ultima Genomics 'Using Ultima Genomics technology to detect minimal residual disease'
09:30-09:40 Q&A: 09:40-09:45	Karen-Lise Garm Spindler Aarhus University, Denmark 'Using ctDNA for response evaluation in solid tumors – a paradigm shift in medical oncology?'
09:45-10:05 Q&A: 10:05-10:15	Peter Ulz Medical University Graz, Austria Proffered Paper 4: 'Landscape of somatic copy-number alterations in advanced breast, prostate and colorectal cancers by longitudinal shallow whole-genome sequencing of cell-free DNA'
10:15-10:35 Q&A: 10:35-10:45	Ellen Heitzer Medical University Graz, Austria 'Signal vs noise: The reality of ctDNA in advanced disease'
	Irene Casanova VHIO, Spain 'EV-enhanced liquid biopsy for tumor dynamics in metastatic prostate cancer'

10:45-11:15

11:15-11:35

Q&A: 11:35-11:45

11:45-11:55

Q&A: 11:55-12:00

12:00-12:10

12:10-12:30

Q&A: 12:30-12:40

12:40-13:30

13:30-15:00

15:00-15:20

Q&A: 15:20-15:30

15:30-15:40

Q&A: 15:40-15:45

15:45-16:05

Q&A: 16:05-16:15

16:15-16:45

16:45-17:05

Q&A: 17:05-17:15

17:15-17:35

Q&A: 17:35-17:45



COFFEE BREAK & EXHIBITION

François Clément Bidard Institut Curie &

UVSQ/Université Paris-Saclay, France

'Intercepting late resistance to therapy with ctDNA: ESR1 mutations and beyond'

Galatea Kallergi University of Patras, Greece

Proffered Paper 5: 'Unraveling the Phenotypic Heterogeneity of Tumor-Derived Cells in the Bloodstream of Pancreatic Cancer Patients'

POSTER SPOTLIGHTS

Posters 90 and 120 will be presented in 3-minute 'flash talks'

BECTON DICKINSON SYMPOSIUM

Markus Wolf PreAnalytix

'From Blood Draw to Insight: Key Considerations in Preparing Diagnostic Liquid Biopsy Specimens for ccfDNA Analysis'



LUNCH & EXHIBITION

POSTER DISCUSSION SESSION 2

Presenters of posters 62-123 should stand by their boards

SESSION 3: FRONTIERS IN LIQUID BIOPSY TECHNOLOGY - FROM FRAGMENTOMICS TO FUNCTIONAL READOUTS

Chair: Nikolas Stoecklein

Mette Aaegebeck University of Copenhagen, Denmark

'Oncofetal Chondroitin Sulfate: A circulating biomarker on tumour-derived CTCs, EVs, and soluble proteoglycans'

Anton Fornies Marine IDIBAPS, Spain

Proffered Paper 6: 'Cell type signatures derived from cfDNA fragmentation profiles in patients with melanoma or benign melanocytic lesions'

Nikolas Stoecklein University of Dusseldorf, Germany

'From Milliliters to Liters: Diagnostic Leukapheresis Enables High-Volume Liquid Biopsy for Rare CTC Detection'



COFFEE BREAK & EXHIBITION

An Hendrix Ghent University, Belgium

'Extracellular vesicle-based biomarkers: from technology towards biomedical application'

Anders Jacobsen Skanderup Genome Institute of Singapore

'Toward Scalable Tumor-Naïve ctDNA Quantification'

Take down
session 1
posters

Session 2
posters can be
put up

17:45-18:30

PANEL DISCUSSION

'Publication strategies and the responsible use of AI in scientific writing'

19:30



OPTIONAL CONFERENCE DINNER (SOLD OUT)

The conference dinner will be held at the atmospheric La Maison Restaurant (separate ticketed event).

Day 3 | Thursday 24 September

08:15-08:45

EARLY POSTER VIEWING

SESSION 4: LIQUID INSIGHTS AT THE EARLIEST STAGE - TRANSFORMING LOCALISED CANCER DETECTION AND INTERVENTION Chair: An Hendrix

08:45-09:00

PARTICLE METRIX SPOTLIGHT

Bertrand Damart Particle Metrix

'ZetaView Evolution: a new edge for nanoparticle characterization'

09:00-09:30

Q&A: 09:30-09:45

KEYNOTE LECTURE

Maximilian Diehn Stanford University, USA

'Analysis of cell-free RNA for cancer detection and characterization'

09:45-10:05

Q&A: 10:05-10:15

Claus Lindbjerg Andersen Aarhus University, Denmark

'From Resection to Recurrence Prediction: The Role of Liquid Biopsy in CRC Management'

10:15-10:25

Q&A: 10:25-10:30

Christopher Sng Institute of Cancer Research, UK

Proffered Paper 7: 'Augmenting circulating tumour DNA (ctDNA) recurrence prediction in resected colorectal cancer (CRC) through primary tumour genome sequencing'

10:30-11:00



COFFEE BREAK & EXHIBITION

11:00-11:20

Q&A: 11:20-11:30

Nickolas Papadopoulos John Hopkins Medicine, USA

'Quantification of disease burden in acute myeloid leukemia patients'

11:30-11:50

Q&A: 11:50-12:00

Angela DeMichele Penn Medicine, USA

'ctDNA in the neoadjuvant and adjuvant management of breast cancer: the quest for clinical utility'

12:00

SUMMARY, AWARDS AND DEPART

Travel grants

More information about EACR grants: eacr.org/travel-grant

EACR-Worldwide Cancer Research Travel Grants provide funds to help early-career EACR members and researchers based in low- or middle-income economy countries to participate in our conferences.

Congratulations to the recipients of the travel grants for this conference. Each recipient received a full registration free of charge and funds to assist with travel and accommodation costs.

- **SHERIEN EL-DALY** EGYPT
- **ANTON FORNIES MARINE** SPAIN
- **SANGMI LEE** USA
- **MISCHA STEKETEE** NETHERLANDS
- **ROMA SUNDER** SPAIN

worldwide
cancer
research

EACR
European Association
for Cancer Research

Supporters

Our thanks to the following partners for supporting us in promoting this conference:

eatris


MRS METASTASIS
RESEARCH SOCIETY



Molecular
Oncology

ecancer

Venue and exhibitors



ADELIS Stand: 1

Website: www.adelis-tech.com

Represented at the conference by:

Audrey Boutonnet, Frédéric Ginot



Izon Science Stand: 2

Website: www.izon.com

Represented at the conference by:

Marianne Marchioni



Becton Dickinson Stand: 3

Website: www.bd.com

Represented at the conference by:

Astrid Provoost, Safouene Fatnassi, Markus Wolf, Karlo Svrze



Symposium: Wednesday | 12:10-12:40

Markus Wolf Pre-Analytix, Senior Scientist R&D

'From Blood Draw to Insight: Key Considerations in Preparing Diagnostic Liquid Biopsy Specimens for ccfDNA Analysis'

Revvity Stand: 4
Website: www.revvity.com
Represented at the conference by:
Abhay Joshi

revvity

Rarity Bioscience Stand: 5
Website: www.raritybioscience.com
Represented at the conference by:
Loora Laan, Feri Shahin

 rarity
BIOSCIENCE

De Gruyter Brill Stand: 6
Website: www.degruyterbrill.com/journal
Represented at the conference by:
Izabela Żarczyńska


De Gruyter Brill

METHYS Dx Stand: 7
Website: www.methysdx.com
Represented at the conference by:
Valérie Taly, Samuel Bouvet, Magali Droniou

METHYS DX

n6 Stand: 8
Website: www.n6tec.com
Represented at the conference by:
Yann Jouvenot



TargetingOne Stand: 9
Website: www.targetingone.com
Represented at the conference by:
Pei Yang

 新羿生物
TARGETINGONE

Cyclomics Stand: 10
Website: www.cyclomics.com
Represented at the conference by:
Wigard Kloosterman, Aska Przewrocka

 Cyclomics
next-gen liquid-biopsy diagnostics

Twist Bioscience Stand: 11
Website: www.twistbioscience.com
Represented at the conference by:
Tiphaine Godefroy

T W I S T
BIOSCIENCE

Bruker Optics GmbH & Co. Stand: 12
Website: www.bruker.com/inta
Represented at the conference by:
Martin Blessing

 BRUKER

Promega Stand: 13

Website: www.promega.com

Represented at the conference by:

Isabelle Prost, Baptiste Almuneau



Vazyme Hungary Korlátolt

Felelősségű Társaság Stand: 14

Website: www.vazymeglobal.com

Represented at the conference by:

Francesco Mazzarelli, Simone Notaro



Particle Metrix Stand: 15

Website: www.particle-metrix.com

Represented at the conference by:

Bertrand Damart



Spotlight: Thursday | 08:45-09:00

Bertrand Damart Particle Metrix

'ZetaView Evolution: a new edge for nanoparticle characterization'

biomodal Stand: 16

Website: www.biomodal.com

Represented at the conference by:

Tom Charlesworth, Annelie Johansson, Pawel Gardzielewski



Symposium: Wednesday | 16:40-17:10

Tom Charlesworth Director of Market Strategy & Corporate Development, biomodal

'Single stranded 6-base workflow optimises discovery of integrated genetic, epigenetic and fragmentomic biomarkers for sensitive ctDNA detection.'

Ultima Genomics Stand: 17

Website: www.ultimagenomics.com

Represented at the conference by:

Alex Watkins, Mickael Ploquin



Spotlight: Wednesday | 08:45-09:00

Alex Watkins Staff Field Applications Scientist Ultima Genomics

'Using Ultima Genomics technology to detect minimal residual disease'

Poster index

View abstracts when logged in at www.eacr.org/conference/liquidbiopsies2026

Poster Spotlight session 1: Tuesday, 16:30 | Also as posters on Tuesday

1 Improving paediatric cancer care by leveraging a new ultra-sensitive ctDNA assay
Presented by Wenhan Chen, Children's Cancer Institute, and School of Clinical Medicine, UNSW Medicine & Health, Sydney, AUSTRALIA

30 Nucleosomal profiling infers ER status in longitudinal breast cancer liquid biopsies
Presented by Kate Glennon, DKFZ, DTKK and NCT, Heidelberg, GERMANY

55 Cell-Free DNA Genomic and Fragmentomic Features for Early Outcome Prediction in Large B-Cell Lymphoma
Presented by Parisa Mapar, Amsterdam UMC, and Cancer Center Amsterdam, NETHERLANDS

Poster Spotlight session 2: Wednesday, 12:00 | Also as posters on Wednesday

90 M-PACT-GLOBAL: a pediatric pan-cancer classifier for cell-free DNA methylomes
Presented by Kyle Smith, St. Jude Children's Research Hospital, Memphis, USA

120 Longitudinal multimodal liquid biopsy profiling to characterize treatment response dynamics in metastatic Prostate Cancer: Interim results from the MARION clinical study
Presented by Roma Sunder, VHIO, Barcelona, SPAIN

Poster presentations session 1: Tuesday, 18:20 - 19:50

1 [SPOTLIGHT] Improving paediatric cancer care by leveraging a new ultra-sensitive ctDNA assay
Presented by Wenhan Chen, Children's Cancer Institute, and School of Clinical Medicine, UNSW Medicine & Health, Sydney, AUSTRALIA

2 Label-free microfluidic capture of viable circulating tumour cells (CTCs) from integrated transcriptomic and immunophenotyping profiling in metastatic NSCLC
Presented by Naila Abid, University of Leicester, UK

3 Integrated immunofluorescence and transcriptomic analysis of enriched circulating tumour cells: A streamlined negative selection workflow
Presented by Emmanuel Acheampong, University of Leicester, UK

4 Liquid Biopsy to Guide Treatment Decision in Metastatic Colorectal Cancer: Novel Copy-Number-Variation Biomarkers Anticipating Disease Progression
Presented by Cristina Albuquerque, IPOLFG, Lisboa, PORTUGAL

5 Exploring circRNAs in Pediatric Cancer using Liquid Biopsies
Presented by Ilaria Allevato, Oslo University Hospital Rikshospitalet, NORWAY

6 Circulating tumor DNA guided treatment monitoring in advanced lung cancer - a randomized interventional study
Presented by Michael Andersen, Zealand University Hospital, Roskilde, and University of Copenhagen, DENMARK

7 Comparing droplet digital PCR and Oxford Nanopore Technologies for longitudinal monitoring of circulating tumor DNA in neuroblastoma
Presented by Lars Baumbusch, Oslo University Hospital, and Østfold University of Applied Sciences, Halden, NORWAY

8 Development of a novel digital PCR multiplex test for improved ovarian cancer disease monitoring
Presented by Shannon Beattie, GenoME, Belfast, UK

9 Using single stranded-based cfDNA library building for detecting methylation levels
Presented by Tibor Bedekovics, Mayo Clinic, Rochester, MN, USA

10 Development of an aptamer-functionalized mesh for a low shear stress capture and release of circulating tumor cells
Presented by Daan Beijersbergen, Haute Ecole Arc, Neuchâtel, and University of Bern, SWITZERLAND

- 11 Assessing the Potential of Liquid Biopsy for the Clinical Management of Young Adult Patients with Non-Small Cell Lung Cancer [Presented by Federica Benso, University of Turin, San Luigi Gonzaga Hospital, Turin, ITALY](#)
- 12 Surface profiling of circulating extracellular vesicles captures liver disease progression and predicts immunotherapy response in hepatocellular carcinoma [Presented by Mathieu Boissan, Sorbonne Université, INSERM, Paris, FRANCE](#)
- 13 Longitudinal monitoring of HER2 amplification in circulating tumor DNA of metastatic breast cancer patients treated with trastuzumab deruxtecan [Presented by Fabiana Bettoni, Hospital Sirio-Libanês, São Paulo, BRAZIL](#)
- 14 Cell-Free DNA Methylation Testing for Facilitating the Early Detection and Monitoring of Colorectal Cancer [Presented by Orsolya Biro, Clinomics Europe Ltd., and Semmelweis University, Budapest, HUNGARY](#)
- 15 Liquid Biopsy in DLBCL: A Comparative Study of CAPP-Seq and WES for Dynamic Disease Tracking [Presented by Tamara Bittolo, CRO, IRCCS, Aviano, ITALY](#)
- 16 Ultrasound-mediated blood-brain barrier disruption for improved drug delivery and liquid biopsy profiling in pediatric brain tumors [Presented by Anne-Florence Blandin, Gustave Roussy, Villejuif, FRANCE](#)
- 17 Triple-negative breast cancer metastatic xenograft model for efficient isolation of circulating tumour cells and their single-cell characterization [Presented by Tomasz Buko, University of Warsaw, POLAND](#)
- 18 Prioritization of plasma cell-free DNA methylation candidates for ddPCR assay development in pancreatic ductal adenocarcinoma [Presented by Katarína Buranovska, Slovak Academy of Sciences, Bratislava, SLOVAK REPUBLIC](#)
- 19 Plasma KRAS dynamics and prognostic value in advanced lung adenocarcinoma [Presented by Valentina Buzzi, University of Siena, ITALY and University of Florence, ITALY](#)
- 20 DNA Methylation Biomarkers for Liquid Biopsy-Based Risk Stratification of Localised Prostate Cancer [Presented by Jodie Byrne, JCRC Queen's University Belfast, UK](#)
- 21 HFX: whole-void urine extraction enables amplification-free urinary cfDNA multi-omics [Presented by David Calderón Franco, Hologenomix B.V., Delft, NETHERLANDS](#)
- 22 Single-cell low-pass methylation profiling reveals tumor origin and molecular identity of circulating tumor cells [Presented by Mathieu Carrere, CRCT, Toulouse, FRANCE](#)
- 23 Post-surgical Analysis of Circulating Tumour Cell Predicts Progression-Free Survival in patients with localised Colorectal Cancer [Presented by Sandra Carvalho, RUBYnanomed, Braga, PORTUGAL](#)
- 24 Removal of end-repair from liquid biopsy library preparation reduces hypomethylation artefacts and improves fragment-level accuracy in duet cfDNA assays for improved ctDNA detection and tissue of origin determination [Presented by Tom Charlesworth, biomodal Ltd, Cambridge, UK](#)
- 25 Serial organ-resolved cfDNA tissue of origin analyses detects metastases up to six months before radiological confirmation [Presented by Julian Lidberg, Lund University, SWEDEN](#)
- 26 pH Responsive Skin Patches Interrogate Interstitial Skin Fluid to Improve Diagnosis of Skin Cancer Lesions in Primary Care [Presented by Dimitrios Chatzimpalasis, Imperial College London, UK](#)
- 27 Isolated atypical circulating cells are megakaryocytes that can predict response to neoadjuvant treatment in breast cancer patients [Presented by Agathe Cohendet, Aix Marseille Univ, CNRS, INSERM, CRCM, Marseille, FRANCE](#)

- 28 Leveraging cfDNA epigenetic profiling using nanopore sequencing for better treatment and prognosis in solid cancers [Presented by Supriya Dash, University of Augsburg, GERMANY](#)
- 29 Beyond Tumor Shedding: A Blood-Based Epitranscriptomic Platform for Very Early Cancer Detection [Presented by Alexandre David, Institut de Recherche en Cancérologie de Montpellier, FRANCE](#)
- 30 [SPOTLIGHT] Nucleosomal profiling infers ER status in longitudinal breast cancer liquid biopsies [Presented by Kate Glennon, DKFZ, DKTK and NCT, Heidelberg, GERMANY](#)
- 31 Improving Liquid Biopsy Informative Value Through Robust Tumor Fraction Estimation in non invasive somatic mutation detection [Presented by Marie de Barsy, Institut de Pathologie et de Génétique, Gosselies, BELGIUM](#)
- 32 Discovery of biomarkers indicative for the effect of prehabilitation on resilience and postoperative outcome in CRC patients undergoing elective surgery [Presented by Margot de Looft, Hanze University of Applied Sciences, Groningen, NETHERLANDS](#)
- 33 "Urinary protein 1" as a stratification and neoadjuvant chemotherapy response non-invasive biomarker in muscle-invasive bladder cancer [Presented by Gisela de Miguel, Debios Diagnostics SL, Badalona, and Universitat Autònoma de Barcelona, Bellaterra, SPAIN](#)
- 34 Fragmentomic analysis of circulating cell-free DNA indicates altered nucleosomal organization patterns in liver disease [Presented by Jerome Denis, Sorbonne Université, INSERM, and Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, PARIS, FRANCE](#)
- 35 Extracellular Vesicle Subtype Composition Is Associated with Histotype and Transcriptomic Programs in Pleural Mesothelioma [Presented by Nikolett Kitti Dobos, Pázmány Péter Catholic University, Budapest, HUNGARY](#)
- 36 Integrated analysis of ctDNA concentration, fragmentation, and mutational profiles provides prognostic information in Follicular Lymphoma [Presented by Benedetta Donati, Azienda USL-IRCCS di Reggio Emilia, ITALY](#)
- 37 Molecular determinants of treatment response to targeted PI3K therapy in advanced breast cancer with PIK3CA mutant circulating tumour DNA [Presented by Ankit Dutta, Peter MacCallum Cancer Centre, Melbourne, and University of Melbourne, VIC, AUSTRALIA](#)
- 38 Integrative Profiling of Circulating Exosomal miRNA Signatures as Liquid Biopsy Biomarkers for Breast Cancer Grading and Metastatic Stratification [Presented by Sherien El-Daly, National Research Centre, Cairo, EGYPT](#)
- 39 Integrated cerebrospinal fluid liquid biopsy enables single-cell and cell-free multi-omic profiling of leptomeningeal metastases and pediatric brain tumors [Presented by Giancarlo Feliciello, Fraunhofer ITEM, Regensburg, GERMANY](#)
- 40 Improving Extracellular vesicle Isolation for liquid biopsy using a nanobody-functionalized magnetic platform [Presented by Lidija Filipovic, University of Belgrade, SERBIA](#)
- 41 Adaptation and Technical Feasibility of a Tissue-Designed Custom Twist NGS Panel for Plasma cfDNA Profiling in Colorectal Cancer Patients and Cancer-Free Lynch Syndrome Carriers [Presented by Yulia Fridland, Comenius University in Bratislava, SLOVAK REPUBLIC](#)
- 42 Pre-diagnostic circulating antibody responses to bacterial antigens and subsequent colorectal cancer-specific and overall survival in the EPIC cohort [Presented by Harsha Ganesan, University College Dublin, IRELAND](#)
- 43 Concordant and dynamic cfDNA methylation signatures reflect disease progression in metastatic pancreatic cancer [Presented by Maria Victoria Garcia Ortiz, University of Córdoba, and CIBERONC, Madrid, SPAIN](#)

- 44 Fragment-level integration of epigenetic and genetic signals for ultra-sensitive ctDNA detection in liquid biopsy and MRD applications [Presented by Pawel Gardzielewski, biomodal, Cambridge, UK](#)
- 45 Fragmentomics-derived transcriptional activation score refines prognostic stratification in metastatic castration-resistant prostate cancer [Presented by Simon Garinet, Assistance Publique Hopitaux de Paris, and Université Paris Cité, FRANCE](#)
- 46 Expanding the Value of CellSave Blood Samples Through Extracellular Vesicle Proteomics [Presented by Andrés Garisoain, Heine University Düsseldorf, GERMANY](#)
- 47 Evaluation of the Genesis System for Cancer Cell Isolation/Enumeration in Liquid Biopsy Samples [Presented by Kathy Gately, Trinity College Dublin & St James's Hospital, Dublin, IRELAND](#)
- 48 Development of an Extracellular Vesicle Surface Marker Platform for Liquid Biopsy Applications in Lung and Pancreatic Cancer [Presented by Laura Grech, University of Malta, Msida, MALTA](#)
- 49 MRD Express: Rapid, Scalable, and High-Performance Custom Target Enrichment for Minimal Residual Disease Monitoring [Presented by Tina Han, Twist Bioscience, San Francisco, CA, USA](#)
- 50 Global genomic instability and mutational pattern analysis in plasma from an ovarian cancer cohort using low-coverage whole-genome sequencing [Presented by Zuzana Hanzliková, Comenius University, and Geneton Ltd., Bratislava, SLOVAK REPUBLIC](#)
- 51 Implementation and Validation of a Liquid Biopsy-Based MRD Assay for DLBCL in Routine Clinical Diagnostics [Presented by Manuela Harloff, MLL Munich Leukemia Laboratory, GERMANY](#)
- 52 Longitudinal changes in the miR-17-92 cluster, miR-143-3p and RAS mutation dynamics in liquid biopsy during treatment of metastatic colorectal cancer [Presented by Natálie Hříbková, Charles University, Pilsen, and National Institute of Public Health, Prague, CZECH REPUBLIC](#)
- 53 Circulating multinucleated giant cells derived from tumour-macrophage fusion orchestrate pancreatic cancer metastasis [Presented by Chun-Mei Hu, Academia Sinica, Taipei, TAIWAN ROC](#)
- 54 Plasma cfDNA copy-number and fragmentomic profiling captures sarcoma-associated and karyotype-related features [Presented by Myesha Jahin, DKFZ, Heidelberg, GERMANY](#)
- 55 [SPOTLIGHT] Cell-Free DNA Genomic and Fragmentomic Features for Early Outcome Prediction in Large B-Cell Lymphoma [Presented by Parisa Mapar, Amsterdam UMC, and Cancer Center Amsterdam, NETHERLANDS](#)
- 56 Ex vivo expansion and transcriptomic characterization of CTC-derived cell line from a 4T1 murine breast cancer model [Presented by Tanja Jesenko, Institute of Oncology Ljubljana, and University of Ljubljana, SLOVENIA](#)
- 57 Precision characterization of extracellular vesicles via interferometric nanoparticle tracking analysis (iNTA) and sensitive fluorescence measurement [Presented by Shuhan Jiang, Max Planck Institute for the Science of Light, and Max-Planck-Zentrum für Physik und Medizin, Erlangen, GERMANY](#)
- 58 Integrated 6-base cfDNA profiling reveals complementary genetic, epigenetic and fragmentomic biomarkers, enabling the selection of the most powerful biomarker combinations for cancer detection [Presented by Annelie Johansson, biomodal, Cambridge, UK](#)
- 59 Tracking tumour evolution in cell-free DNA: The role of genomic changes in metastatic breast cancer [Presented by Solon Karapanagiotis, University of Cambridge, UK](#)

60 Tracking Dissemination at the Source: Tumor-Draining Vein Liquid Biopsies in Gastroesophageal Cancer Presented by Jennifer Kluczny, Heinrich Heine University Düsseldorf, GERMANY

61 Hydrogel Microneedle Patch for Diagnosis of Skin Cancer Based on miRNA Profiling in Interstitial Skin Fluid Presented by Janavi Kotamarthi, Imperial College London, UK

Poster presentations session 2: Wednesday, 13:30 - 15:00

62 Tracking the spatial origin of circulating nucleic acids in genetically barcoded neuroblastoma mouse models Presented by Rita Paola Leblans, VIB-UGent, and CRIG, Ghent, BELGIUM

63 Linker-associated nucleosome spacing contributes to cfDNA fragmentation signatures at active regulatory elements Presented by Garyoung Lee, Dana-Farber Cancer Institute, Boston, MA, US

64 Ultra-sensitive sequencing-based tracking of ALK alterations in neuroblastoma for improved therapeutic decision-making (ALK-TRACK) Presented by Aleksandra Letunovska, Princess Maxima Center for Pediatric Oncology, Utrecht, and Cyclomics, Amsterdam, NETHERLANDS

65 *Poster withdrawn*

66 Low-pass multimodal WGS outperforms methylation profiling for cfDNA tissue-of-origin classification Presented by Avril Lim, Genome Institute of Singapore, and National University of Singapore, SINGAPORE

67 Confidence-stratified tumor-of-origin prediction from cfDNA methylation profile Presented by Boris Lipinski, Aima, Grenoble, FRANCE

68 NGS sequencing of CTC from early breast cancer patients identified Chromogranin A as an important contributor to EMT Presented by Boris Lukač, Comenius University in Bratislava, and Slovak Academy of Sciences, Bratislava, SLOVAK REPUBLIC

69 Comparative Genomic Profiling of Cerebrospinal Fluid Supernatant Cell-Free DNA and Cell-Pellet DNA in Lung Cancer Patients with Central Nervous System Metastases Presented by Feifei Ma, HaploX Biotechnology, Shenzhen, P.R. CHINA

70 Exosomal miR-1246 as a Potential Liquid Biopsy Biomarker for Prostate Cancer Presented by Suzana Matijašević Joković, University of Belgrade, SERBIA

71 Aqueous humor liquid biopsy: a unique access to ophthalmic tumors Presented by Luigi Mazzeo, University of Lausanne, SWITZERLAND

72 mcPCR: PCR for methylation Presented by David McBride, Syndex Bio Ltd, Foxton, UK

73 An Integrated Methylation and Fragmentomics Pipeline for cfDNA Biomarker Discovery Presented by Charlotte McBrien, GenoME Diagnostics, Belfast, UK

74 MeDIP profiling of ascites identifies Integrin Alpha 4 as a tumour suppressor silenced by DNA methylation and PRC2 in ovarian cancers Presented by Alexander McIntyre, Queens University Belfast, and The All-Ireland CLuB Consortium, Dublin, IRELAND

75 Circulating Tumour Cell-Based Profiling of Antibody-Drug Conjugate Target Antigens: A Workflow for Triple-Negative Breast Cancer and Epithelial Ovarian Cancer Presented by Lauren McMahon, Trinity College Dublin, and Trinity St James Cancer Institute, Dublin, IRELAND

76 A Candidate WHO Multi-Analyte ctDNA Reference Material to Support Harmonisation of Liquid Biopsy Testing Platforms Presented by Abdalla Mohamed, MHRA, London, UK

77 Personalized duplex sequencing for systemic ctDNA monitoring in pediatric sarcoma Presented by Tharaa Mohammad, Quantitative Genomic Medicine Laboratories, and Veritas Genetics, Barcelona, SPAIN

- 78 Heterogeneous cell-free RNA alterations in plasma enable classification of cancer patients and controls [Presented by Annelien Morlion, Ghent University, and Cancer Research Institute, Ghent, BELGIUM](#)
- 79 The development of novel liquid biopsy tests for the improved diagnosis of Pancreatic Cancers [Presented by Paul Mullan, Queen's University Belfast, UK](#)
- 80 Comprehensive liquid biopsy profiling for AML [Presented by Aonghus Naughton, Karolinska Institutet, Stockholm, SWEDEN](#)
- 81 Correlation of cell-free DNA concentration and fragmentomics with PET/CT parameters in high-grade non-Hodgkin lymphoma [Presented by Clíodhna Nolan, University College Cork, IRELAND](#)
- 82 Longitudinal transcriptomic profiling of immune cells in NSCLC patients treated with immune checkpoint inhibitors: comparison of long-term and short-term benefit [Presented by Anne Nørholm Rasmussen, Aarhus University Hospital, DENMARK](#)
- 83 Novel ctDNA methylation markers for risk stratification of patients with resectable NSCLC [Presented by Hannah O'Toole, Trinity College Dublin, IRELAND](#)
- 84 Benchmarking Illumina 5-base against matched bisulfite sequencing for cfDNA tumor fraction estimation and subtyping in breast cancer [Presented by Tommaso Orioli, University of Florence, ITALY](#)
- 85 Combined analysis of Circulating Tumor Cells and Extracellular Vesicles identifies prognostic and diagnostic biomarkers in Non-Small Cell Lung Cancer [Presented by Dimitrios Papakonstantinou, University of Patras, GREECE](#)
- 86 Analysis of an immune-derived long non-coding RNAs signature in plasmatic extracellular vesicles for improving outcomes in colorectal cancer patients [Presented by Marco Peluso, ISPRO, Florence, ITALY](#)
- 87 Single-cell genomic profiling of CTCs and CTC clusters reveals mutational heterogeneity in metastatic breast cancer [Presented by Roberto Piñeiro Cid, Oncomet, Health Research Institute of Santiago de Compostela \(IDIS\), and CIBERONC, Madrid, SPAIN](#)
- 88 Tzu Cancer Therapeutics: a new company that bases cancer therapy on the deep analysis of DNA, mRNA and proteins of Circulating Tumor Cells [Presented by Ronald Plasterk, Tzu Cancer Therapeutics, Amsterdam, NETHERLANDS](#)
- 89 From tumor tissue to liquid biopsy: FFPE proteomics identifies circulating biomarker candidates for colorectal cancer detection [Presented by Daniel Pons, Universitat de les Illes Balears, IdISBa, Palma, SPAIN,](#)
- 90 [SPOTLIGHT] M-PACT-GLOBAL: a pediatric pan-cancer classifier for cell-free DNA methylomes [Presented by Kyle Smith, St. Jude Children's Research Hospital, Memphis, USA](#)
- 91 Multimodal ctDNA profiling for cancer detection and monitoring in pan-cancer patients with advanced disease enrolled in the SHIVA02 trial [Presented by Charlotte Proudhon, University of Rennes, FRANCE](#)
- 92 Ultra-Low-Pass multimodal Nanopore sequencing enables layer-resolved cfDNA profiling in metastatic colorectal cancer [Presented by Blanche Riquier-Morcant, Univ. Montpellier, FRANCE](#)
- 93 Exploring the practical limits of ultra-sensitive cfDNA duplex sequencing: relationships between input material, sequencing depth, and detection sensitivity [Presented by Andreas Risch, MGZ München, GERMANY](#)
- 94 Circulating Exosomal microRNAs as Longitudinal Liquid Biopsy Biomarkers in Diffuse Midline Glioma H3K27-altered [Presented by Muhammad Rizwan, IRCCS, Rome, ITALY](#)

95 Clinical validity of tumor-agnostic ctDNA for recurrence detection after surgery in non-small cell lung cancer patients Presented by Laerke Rosenlund, Aarhus University Hospital, DENMARK

96 Improving the Early detection and diagnosis of Breast Cancers using methylated circulating tumour DNA Presented by Micheal Ryan, Queens University Belfast, IRELAND

97 FRAGILE-FLOW: a reproducible Nextflow pipeline for multi-modal fragmentomic analysis of cell-free DNA Presented by Aram Safrastyan, University of Manchester, UK

98 Isolation of CTCs and CTMs using size based CellBio a2000TM system in Non-Small Cell Lung Cancer (NSCLC) patients Presented by Petros Sarantos, General Biologicals Corp, Zhubei City, TAIWAN ROC

99 A Prospective Biobanking and Data Handling Strategy of Blood Samples to Enable Comprehensive Multi-Modal Testing in Cancer Patients Presented by Kathleen Schoofs, VIB-UGent, and Cancer Research Institute Ghent, BELGIUM

100 Hypermethylated cfDNA fragments allow the detection of circulating tumour DNA in BRCA1/2-associated breast and ovarian cancer patients Presented by Christopher Schroeder, Institute of Medical Genetics and Applied Genomics, Tübingen, and Institute for Hereditary Cancer Syndromes, Cologne, GERMANY

101 Extending gastric cancer sex-disparity findings to liquid biopsy: sex-aware cfDNA 5hmC signals reinforce tumor DNA-repair disparities Presented by Dorit Shweiki, The Academic College of Tel Aviv Yaffo, ISRAEL

102 Comparative Analysis of Circulating Tumor Cell and Cluster Dynamics in Preclinical 4T1 Models of Metastatic Breast Cancer Presented by Veronika Skrjanc, Institute of Oncology Ljubljana, and University of Ljubljana, SLOVENIA

103 Ultra-high sensitive detection and molecular characterization of circulating tumor cells during minimal residual disease in breast cancer Presented by Jessica Sonntag, University Hospital Düsseldorf, and Heinrich-Heine-University, Düsseldorf, GERMANY

104 PEAR-OP: accelerating personalized medicine through multi-omics Nanopore cfDNA profiling for longitudinal lung cancer monitoring Presented by Francesca Maria Stefanizzi, Luxembourg Institute of Health, Strassen, LUXEMBOURG

105 A novel platform for high-yield tumor cell isolation and phenotypic characterization from malignant effusions Presented by Flavie Straub, Claude Bernard Lyon 1 University, and SmartCatch, Toulouse, FRANCE

106 Not all CTCs wear EpCAM. Identifying complementary targets for antibody-based CTC enrichment Presented by Ewa Szymanek, University of Warsaw, POLAND

107 HRD status and mutation concordance using ascites-derived cfDNA in high-grade serous (HGSC) ovarian cancer: impact of sample type, cytology and treatment setting Presented by Gaelle Tachon, Centre Leon Berard, Lyon, FRANCE

108 RAD51 Immunofluorescence in Circulating Tumour Cells as a Dynamic Biomarker for Monitoring and Predicting PARP Inhibitor Resistance in BRCA/PALB2-mutated Metastatic Breast Cancer Presented by Yarden Toiber Kent, Imperial College London and The Institute of Cancer Research, London, UK

109 Liquid biopsy-based biomarkers for predicting prognosis in metastatic pancreatic cancer Presented by Marta Toledano Fonseca, University of Córdoba, and CIBERONC, Madrid, SPAIN

110 Plasma extracellular vesicle proteomics identifies a malignancy-associated signature in extrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma Presented by Margalida Torrens-Mas, Universitat de les Illes Balears, IdISBa, Palma, SPAIN


111 ctDNA Detection in Early-Stage Resectable NSCLC: Preliminary Results from a Prospective Feasibility Study Presented by Tommaso Trisciuglio, University of Turin, ITALY

- 112 Longitudinal Plasma Cytokine Profiling Reveals Immune Trajectories Associated With Relapse Risk Beyond Interim Pet/Ct In Classical Hodgkin Lymphoma Presented by Jesús García-Velasco García-Suelto, University Hospital Virgen de la Victoria, and IBIMA Plataforma BIONAND, MÁLAGA, SPAIN
- 113 Standardizing the cfDNA fragmentomics landscape: The impact of extraction and sequencing depth Presented by José Luis Villanueva-Cañas, IDIBAPS, Barcelona, and Hospital Clinic Barcelona, SPAIN
- 114 High-throughput plasma proteomic profiling identifies a candidate biomarker to improve early-stage pancreatic ductal adenocarcinoma detection Presented by Stellene Vitaro, Flinders University, Bedford Park, AUSTRALIA
- 115 Liquid biopsy-based multi-omics machine learning for hepatocellular carcinoma detection Presented by Ning Wang, Peter MacCallum Cancer Centre, Melbourne, and University of Melbourne, Victoria, AUSTRALIA
- 116 Time-course PBMC transcriptomics for predicting neoadjuvant therapy response in early Triple-Negative Breast Cancer: a longitudinal proof-of-concept study Presented by Madelaine White, University of Leicester, UK
- 117 Mechanism-Driven Colorectal Cancer Detection through Hologenomic Integration of Rectal Mucus Multiomics Presented by Daniel Wise, Origin Sciences Ltd, Cambridge, UK
- 118 Automated Enrichment of Circulating Tumour DNA Using NaME-PrO for Scalable and Cost-Effective Liquid Biopsy Presented by Nathan Wu, Heriot-Watt University, Edinburgh, UK
- 119 Quantitative benchmarking of Next Generation Sequencing for ctDNA analysis Using Digital PCR Reference Measurement Procedures Presented by Dilek Yener, National Measurement Laboratory at LGC, Guildford, and University of Leeds, UK
- 120 [SPOTLIGHT] Longitudinal multimodal liquid biopsy profiling to characterize treatment response dynamics in metastatic Prostate Cancer: Interim results from the MARION clinical study Presented by Roma Sunder, VHIO, Barcelona, SPAIN
- 121 Tracking prostate cancer evolution from the blood: correlative analyses from ZZ-FIRST clinical trial Presented by Francesca Zacchi, VHIO, Barcelona, SPAIN, and University of Verona, ITALY
- 122 Oncofetal chondroitin sulfate-modified proteoglycans as circulating biomarkers for colorectal cancer Presented by Maj Sofie Ørum-Madsen, University of Copenhagen, and VarCT Diagnostics, Frederiksberg, DENMARK
- 123 Detection of circulating tumor DNA using low-pass whole genome sequencing in soft tissue sarcoma Presented by Paul van der Leest, NKI, Amsterdam, NETHERLANDS



LIQUID BIOPSY ON YOUR BENCHTOP

- Earlier diagnosis
- Higher selectivity
- Higher sensitivity
- Reduced costs
- No sample preparation



**ASTRO® enables automated isolation of all CTC phenotypes
for biomarker analysis, enabling patient monitoring, and
precision oncology.**

**Research Use Only, FDA clearance expected 2027*



Visit website

www.rubynanomed.com



Notes

Notes

Communication.
Collaboration.
Community.

EACR

European Association
for Cancer Research



**NOT A MEMBER
YET? JOIN NOW**

Apply for funding
to develop your
research &
expand
your
horizons



Benefit from
reduced
registration
rates at EACR
events

Join our online
networking
events



Build new
connections
with our 'Find a
Collaborator'
tool

Search
the EACR
Member
Network
and message
other members



Share your
perspective: write
for The Cancer
Researcher
magazine

Access
our free
expert
webinars on
research &
careers



Stay informed
with regular
updates on
news, jobs, and
conferences

Volunteer for
our Ambassador
Programme or
committees

SINGLE CELL BLOOD ANALYSIS

Collect samples anywhere. Process when you're ready.

Easy collection. Single cell resolution. Impactful results.

Single cell profiling and blood samples are a powerful combination, but the realities of translational research don't match up with traditional workflows.

Our new **Flex Apex** protocols fix that, meeting the complexities of multi-site and large cohort studies with easy, streamlined sample handling.

Clinically derived samples have a lot to tell you. Their stories could change everything, and we want to make sure you can tell them.

NEW! Protocol highlights:

- Stabilize blood at the moment of collection for easier multi-site studies
- Collect blood samples anywhere, no need for lab access or intervention at the collection site
- Keep samples at room temperature or 4°C for up to 3 days, or freeze long-term before processing
- Capture deeper insights with options for protein or TCR/BCR profiling

Real-world use cases for convenient, simple sample collection:

Long-term storage

Plan for future analysis with long-term storage between sample collection and processing

Archival samples

Gain new insights with single cell analysis of frozen archival blood samples from previous studies

Multi-site studies

Profile samples in a central location following distributed blood collection, without on-site processing

Populations of interest

Target key populations of interest (e.g., T cells, B cells, or granulocytes) from clinically derived samples

Cell-type enrichment

Stain for protein and perform flow-based enrichment of CD8+ T cells before analysis

Multiple timepoints

Run longitudinal studies and time courses without introducing batch effects

Learn more about single cell blood sample analysis with Apex

[Get started with access to technical articles and validation data >](#)



Contact us

10xgenomics.com | info@10xgenomics.com

© 2026 10x Genomics, Inc. FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.

EACR Industry Partners

The European Association for Cancer Research gratefully acknowledges its Industry Partners, who offer ongoing support to the EACR and provide the means for the association to develop important initiatives.

